Clinical and radiological features of pseudoprogression in brain tumors treated with immune checkpoint inhibitors
PsP is a frequent complication of ICIs. We describe 4 symptomatic patients with pseudoprogression, challenging the iRANO criteria that recommend excluding this diagnosis in symptomatic cases. Clinical impairment should not automatically rule out pseudoprogression, and each case requires thorough evaluation. High PD-L1 expression and greater tumor burden may be associated with PsP, but further studies are needed to confirm these findings.
Authors
- Luís Bataller (ORCID: https://orcid.org/0000-0002-2471-4492)
- Maria José Ibáñez-Juliá
- Agustí Alentorn (ORCID: https://orcid.org/0000-0002-7220-2686)
- Ludovic Nguyen-Them
- Francisco Javier Cabello-Murgui
- Alba Torres-Martínez
- Miguel Mazón-Momparler
- Regina Gironés-Sarrió
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Hospital Universitari i Politècnic La Fe (ES)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institut du Cerveau (FR)
- EAE Business School (ES)
Publication Details
- Journal
- Journal of Neuro-Oncology
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1007/s11060-025-05091-0
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05